Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation
Luigi Nocera(Istituti di Ricovero e Cura a Carattere Scientifico), Alberto Martini(The University of Texas MD Anderson Cancer Center), Daniele Robesti(Vita-Salute San Raffaele University), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Montorsi(Vita-Salute San Raffaele University), Giuseppe Fallara(Istituti di Ricovero e Cura a Carattere Scientifico), Andrea Necchi(Vita-Salute San Raffaele University), Guillaume Ploussard(Clinique Saint Jean Languedoc), Federico Belladelli(IRCCS Ospedale San Raffaele), Pierre I. Karakiewicz(Université de Montréal), Bernard Malavaud(Institut universitaire du cancer de Toulouse Oncopole)
Cited by 7
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k